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The MAP kinase signaling cascade Ras/Raf/MEK/ERK has been involved in a large
variety of cellular and physiological processes that are crucial for life. Many pathological
situations have been associated to this pathway. More than one isoform has been
described at each level of the cascade. In this review we devoted our attention to ERK1
and ERK2, which are the effector kinases of the pathway. Whether ERK1 and ERK2
specify functional differences or are in contrast functionally redundant, constitutes an
ongoing debate despite the huge amount of studies performed to date. In this review we
compiled data on ERK1 vs. ERK2 gene structures, protein sequences, expression levels,
structural and molecular mechanisms of activation and substrate recognition. We have
also attempted to perform a rigorous analysis of studies regarding the individual roles of
ERK1 and ERK2 by the means of morpholinos, siRNA, and shRNA silencing as well as
gene disruption or gene replacement in mice. Finally, we comment on a recent study of
gene and protein evolution of ERK isoforms as a distinct approach to address the same
question. Our review permits the evaluation of the relevance of published studies in the
field especially when measurements of global ERK activation are taken into account. Our
analysis favors the hypothesis of ERK1 and ERK2 exhibiting functional redundancy and
points to the concept of the global ERK quantity, and not isoform specificity, as being the
essential determinant to achieve ERK function.
Keywords: intracellular signaling, MAP kinases, ERK1 and ERK2 isoforms, gene silencing, gene disruption,
expression of isoforms in vertebrates, protein sequence evolution
INTRODUCTION
The Ras/Raf/MEK/ERK cascade is a key signaling pathway which integrates extracellular clues
from cell surface receptors to gene expression and regulation of multiple cellular proteins. ERK
cascade plays a crucial role in multiple cellular processes such as cell proliferation, differentiation,
adhesion, migration and survival. Therefore, it is essential for many physiological events including
development, immunity, metabolism, and memory formation. The core of this pathway consists
in activation of the cascade of three kinases Raf, MEK, and ERK. Raf and MEK are described to
date as cytoplasmic kinases with a single well established substrate, however ERK is unique in this
cascade as it phosphorylates multiple substrates in all cellular compartments (at least 270 substrates
have been identified in proteomics screening von Kriegsheim et al., 2009). MEK and ERK can also
be activated independently of Raf by the COT/TPL2 kinase (Johannessen et al., 2010) and by mos
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during meiotic maturation (Nebreda et al., 1993). Integration
of ERK signaling can also proceed from the regulation of
scaffolding proteins which function mainly to bring several
members of the cascade into close vicinity in order to increase
the efficiency and strength of activation (reviewed in Roskoski,
2012; Cseh et al., 2014). Multiple isoforms have been described
at each step of the Ras/Raf/MEK/ERK pathway (reviewed in
Lefloch et al., 2009). At the levels of Raf and MEK, functional
differences and tissue-specific expression among isoforms have
been clearly established (see Section Search for Specific Functions
of ERK Isoforms). On the other hand, ERK1 and ERK2
seem to be expressed ubiquitously and there are no obvious
regulatory differences inferred from their protein sequences,
their regulation or their sub-cellular localization. The aim of
this review is to put into perspective for the first time the
vast body of work that has attempted to find differential roles
for ERK1 and ERK2 or tried to demonstrate their functional
redundancy.
Prior to scrutinizing studies on ERK isoforms functions, we
will recap the main traits of ERK1/2 regulation, action and role
to aid in understanding the studies on isoform functions.
Overview on ERK Signaling
Before the molecular cloning of ERKs by Melanie Cobb’s
group (Boulton et al., 1990), ERK1 and ERK2 were known
as two proteins respectively p44 and p42 MAPK rapidly
phosphorylated in response to all mitogens (Kohno and
Pouysségur, 1986; Sturgill et al., 1988). The essentiality of
ERK signaling for cell proliferation of mammalian fibroblasts
was first demonstrated by expression of antisense cDNAs
or dominant negative mutants which inhibited global ERK
activity (Pagès et al., 1993). Later, disruption of the erk2 isoform
was shown to induce early embryonic death (Hatano et al.,
2003; Saba-El-Leil et al., 2003; Yao et al., 2003). In adult mice
invalidation of both isoforms, led to animal death within 3 weeks
by multiple organ failures (Blasco et al., 2011). Collectively,
these experiments demonstrate the absolute requirement
for a minimal ERK expression to permit proliferation and
mammalian life.
Using quantitative proteomics, 284 ERK-interacting proteins
have been identified, and 60 of these proteins changed their
own binding to ERK upon induction of differentiation (von
Kriegsheim et al., 2009). ERKs phosphorylate serine or threonine
residues of substrates on the sequence PXS/TP. Many proteins
possess this sequence and are not bona fide ERK substrates.
Specificity is provided by docking motifs located at the back
of the kinase (graphical representation on 3D structure in
Busca et al. (2015). These docking interactions have been
proposed to increase the local concentration of substrates to
favor their phosphorylation when ERK is active. Two motifs
on ERKs bind to substrates, 16 amino-acids that constitute
the common docking site (CDS) also called D-recruitment site
(DRS), and 7 amino-acids that constitute the F-recruitment
site (FRS). The DEJL motif of substrates (docking site for
ERK and JNK, LXL also called KIM, kinase interacting motif)
binds to the DRS (Lee et al., 2004), whereas the DEF (FXFP)
motif of substrates binds to the FRS (Liu et al., 2006). The
duration of ERK activation can lead to phosphorylation of
waves of substrates according to their docking sites content
(Murphy et al., 2004). Of great importance for cell fate, ERKs
phosphorylate multiple transcription factors, hence active ERKs
translocate to the nucleus (Lenormand et al., 1993) mainly by
passive diffusion. This ERK nuclear translocation is certainly
a key process in ERK signaling. Indeed we demonstrated that
retention of active ERK in the cytoplasm abolishes cell cycle
progression and the onset of DNA replication (Brunet et al.,
1999). ERK nuclear translocation is favored by ERKs binding
to the FXFG motif of nucleoporins (Whitehurst et al., 2002), a
motif that mimics the FXFP motif of ERKs substrates. Ideed,
recently it was shown that ERK-mediated phosphorylation of
nucleoporins regulates ERK translocation (Shindo et al., 2016).
Others have indicated that ERKs entry into the nucleus may
require active transport dependent on Ran, especially when
ERKs are fused to beta-galactosidase (Adachi et al., 2000). ERK
nuclear accumulation of ERKs requires synthesis of nuclear
anchors (Lenormand et al., 1998), however nuclear translocation
of ERKs can be regulated by the abundance of interactor proteins,
for example over-expression of PEA-15 can sequester ERK
in the cytoplasm (Formstecher et al., 2001). Similarly, it was
demonstrated that Sef binds to activated forms of MEK, inhibits
the dissociation of the MEK–ERK complex, and blocks nuclear
translocation of activated ERK (Torii et al., 2004). PEA-15 and
Sef expression do not prevent phosphorylation of cytoplasmic
substrates by ERK, however they block activation of nuclear
substrates.
MEK activates ERKs by dual phosphorylation on the
threonine and tyrosine residues of the sequence T185EY187
(sequence of human ERK2). Inactivation of ERKs requires the
removal of either one or both sites of the TEY motif. Tyrosine-
specific phosphatases include PTP-SL, STEP, and HePTP whereas
the threonine-specific phosphatases include protein phosphatase
2A and 2C. A large family of dual specificity phosphatases,
the DUSPs, can inactivate ERKs. A coordinated action of all
these phosphatases induced by ERK is required to shape the
temporal ERK activity for proper mammalian development.
Invalidation of a single ERK phosphatase such as DUSP6
can be sufficient to increase the basal ERKs phosphorylation
level (Li et al., 2007; Maillet et al., 2008). However, DUSP6
invalidation may lead to minor cardiac abnormalities (Maillet
et al., 2008) or a range of phenotypes in the same litter such as
embryonic death, cranio-facial abnormalities or lack of obvious
phenotype (Li et al., 2007). Hence it is difficult to sort out
the precise role of each phosphatase to regulate the activation
level of ERKs during development and adult homeostasis.
Interestingly, in some cases such as the invalidation of DUSP5,
phenotypes appear only upon challenging the pathway. Lack of
DUSP5 in mouse embryo fibroblasts leads to increase nuclear
phospho ERKs content, and lack of DUSP5 in mouse increases
sensitivity to mutant Harvey-Ras (HRasQ61L)-driven papilloma
(Rushworth et al., 2014). As described above, ERKs nuclear
accumulation requires protein neo-synthesis; in fact some of
these nuclear anchors are phosphatases since ERK accumulates
in the nucleus in the dephosphorylated form (Volmat et al.,
2001). DUSP5 is one of the phosphatases that drive ERK
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nuclear accumulation and dephosphorylation (Mandl et al.,
2005).
Pathological Consequences of Abnormal
ERK Signaling
ERK pathway is misregulated via germline mutations in genes
that encode components or regulators of the cascade, causing
disease such as type1 neurofibromatosis and Noonan syndrome
(pathologies clustered under the name rasopathies, Rauen, 2013).
ERK pathway is also over-activated in many cancers. For
example, at the receptor level, the HER2/Neu (EGF family)
oncogene can be over-expressed or mutated leading to persistent
activation of the pathway (Menard et al., 2004). Similarly EGFR
receptor is often mutated in lung and colon cancers (Barber et al.,
2004). At the level of Ras, point activating mutations of K-Ras
are found in over 95% of pancreatic ductal adenocarcinomas
for example (Bryant et al., 2014). Downstream of Ras, the
B-Raf kinase is also mutated in many cancers such as at
least 66% of melanomas (e.g., mutation B-RafV600E; Davies
et al., 2002). At the level of MEK, somatic mutations have
been found via next-generation sequencing of tumoral tissues.
Interestingly, in the langerhans cell histiocytosis disease usually
B-Raf is mutated; however when B-Raf is not mutated, MEK1 is
activated by mutations in 50% of remaining cases (Brown et al.,
2014), highlighting again the importance of ERK pathway in
oncogenesis. It has also been shown that up to 8% of melanomas
present activating mutations of MEK1 or MEK2 (Nikolaev et al.,
2012). At the ERK level, amplification of the ERK2 gene has been
found in tumors of patients treated with anti EGF-receptor kinase
inhibitors. This amplification has been proposed to contribute
to the treatment resistance (Ercan et al., 2012). On the contrary,
loss of small chromosomal segment encompassing one allele of
ERK2 has been observed in children that exhibit microcephaly,
impaired cognition, and developmental delay (Samuels et al.,
2008).
The very high prevalence of human cancers harboring
constitutive activation of the ERK pathway has prompted a
massive development of pharmacological inhibitors targeting
members of the ERK cascade. After the great success of the
tyrosine kinase inhibitor Imatinib to treat chronic myeloid
leukemia (CML) by blocking the kinase activity of BCR-ABL, the
hope was to obtain similar results when treating many cancers
where the driver mutation was in the ERK kinase-cascade. With
kinase inhibitors, CML patients are expected to have a normal
life-expectancy (Jabbour, 2016). However, for cancers arising
from mutations in ERK pathway, patients with mutations at the
levels of receptors (HER/Neu, PDGF, and EGF-receptors) relapse
after some months of treatment. At the level of Ras, targeted
therapies have tried to block the anchoring of Ras at the plasma
membrane unsuccessfully (Baines et al., 2011). At the level of
Raf, inhibitors of the activated form of B-Raf have been approved
recently to treat melanoma, for example PLX4032 (Bollag et al.,
2010). Initially, most patients display dramatic improvements of
the tumor burden, however rapidly resistances to the treatment
arise, leading in most cases to reactivation of ERK pathway.
Resistance can occur from amplification of tyrosine kinase
receptors, acquisition of mutations in N-Ras, amplification of
mutant B-Raf, alternative splicing of mutant B-Raf or even
mutations in MEK protein. Moreover, it has been shown that
inhibitors of B-RafV600E mutant can paradoxically activate the
ERK pathway, especially in the presence of oncogenic Ras. This
was unexpected since B-Raf acts downstream of Ras. However, B-
Raf inhibitors drive the formation of B-Raf/C-Raf hetero dimers,
where the drug-bound partner drives activation of the drug-
free partner through scaffolding or conformational modifications
leading to paradoxical activation of cRAF (Poulikakos et al., 2010;
Hatzivassiliou et al., 2012). Medical hope in this field lays in pan-
Raf inhibitors that target also Src-family of kinases and block all
types of Raf dimers (Girotti et al., 2015) or combined therapies,
for example with inhibitors at other levels of the ERK cascade.
MEK is mainly activated by Raf, however in some cells MEK
has also been described to be activated by the TPL2/Cot pathway.
Therefore, tumors have been shown to escape Raf inhibitors by
re-activating TPL2/Cot (Johannessen et al., 2010). Furthermore,
it has been shown that ERK can retro-phosphorylate MEK1 on
threonine 292 to reduce its activation (Mansour et al., 1994; Saito
et al., 1994), therefore any decrease of Raf activity by inhibitors,
diminishes ERK activity, and as a loop, this decreased ERK
activity reduces retro-inhibition of MEK therefore stabilizing a
threshold of ERK activation. Considering these retro-controls, it
was thought that MEK inhibitors would be better candidates to
target cancers driven by activating mutations in ERK pathway.
Interestingly, the activating lip of MEK kinase is uniquely
structured allowing the design of very potent and specific
kinase inhibitors (Ohren et al., 2004). Two families of MEK
inhibitors have been designed: allosteric inhibitors acting via
binding to the activating lip (e.g., PD184352) and more recently,
classical competitors of ATP-binding that block MEK activity
(e.g., E6201, Narita et al., 2014). Unfortunately, these inhibitors
generate secondary effects in patients and therefore a reduction
of dosage or duration of treatment is imposed, hence after an
initial effectiveness, tumors relapse. Secondary effects observed
during treatment with MEK inhibitors encompass hand and
foot rash, diarrhea, nausea, retinopathy, visual disturbance,
mental status change, alopecia, stomatitis, and verrucous
keratoses (Welsh and Corrie, 2015). In 2013 the MEK inhibitor
Trametinib was approved for the treatment of melanoma
patients with unresectable or metastatic melanoma with BRAF
mutations. As of 2016, many clinical trials are ongoing with
several MEK inhibitors demonstrating the endeavor to cure
cancers and rasopathies (for example: selumetinib/AZD6244;
MEK162; Refametinib/BAY86-9766; Trametinib/ GSK1120212;
GDC-0973; PD-0325901; RO5126766 and Cobimetinib/GDC-
0973).
The resistance to treatments from Raf and MEK inhibitors
has led to clinical trials for combined therapy such treatment
with dabrafenib and trametinib for un-resectable or metastatic
melanoma with a B-RafV600E or B-RafV600K mutations.
Nevertheless, the majority of patients face relapse even with the
combination of treatments by mechanisms which are not yet
understood (reviewed by Queirolo et al., 2015).
Resistance to treatment by inhibitors of RTKs, Raf and MEK
have finally led to target ERK itself. Interestingly even cells
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resistant to MEK or Raf inhibition (for example by mutations
in the kinase pocket of MEK or via amplification of K-Ras
expression) were shown to be sensitive to ERK kinase inhibition
(Hatzivassiliou et al., 2012; Morris et al., 2013). Specific ERK
inhibitors are very difficult to design due to the high homology
between ERK and CDK kinases pockets (these kinases belong to
the same family of CMGC kinases Manning et al., 2002). For
example, the CDK2 inhibitor purvalanol was shown to block
activation of ERK at similar concentrations in-cellulo despite a
higher affinity for purified CDK1/2 protein (Knockaert et al.,
2002). As of 2016, five clinical assays are ongoing with four ERK
inhibitors (MK-8353/SCH900353, BVD 523, RG7842/GDC0994,
and CC-90003). No conclusive results have been reached up to
date but these trials bring new and promising hope.
ORIGIN OF ERK ISOFORMS
In 1991 two isoforms of ERK were discovered in mammals:
ERK1 (MAPK3) and ERK2 (MAPK1) (Boulton et al., 1991).
At that time, two MAP kinases similar to mammalian ERK
were discovered in budding yeast (S. cerevisiae), FUS3 and
KSS1 (Courchesne et al., 1989; Elion et al., 1990) hence one
could consider that two kinase isoforms were necessary from
yeast to humans. However, only one kinase similar to ERK was
discovered in fission yeast (S. pombe), spk1 (Toda et al., 1991).
It is now established that mammalian ERK1/2 isoforms arose
independently from budding yeast MAPK isoforms, therefore
the comparative studies between FUS3 and KSS1 cannot be
transposed to ERK1 and ERK2 studies. Indeed a yeast-specific
whole genome duplication (WGD) led to emergence of FUS3 and
KSS1 (Wolfe et al., 2015), whereas the vertebrate-specific WGD
led to the emergence of ERK1 and ERK2. WGDs are essential
events in the evolution that have been observed in all phylla of
life, whereby an organism possesses initially two copies of its
entire genome. After the duplication event, duplicate genes can
have different fates that participate in speciation as described for
paramecium (Aury et al., 2006). The origin of the duplication
leading to emergence of ERK1 and ERK2 was determined to
be early in the vertebrate phylum (Busca et al., 2015). First
of all, in all tetrapod clades at least one animal expresses two
ERKs that can be phylogenically classified into ERK1 and ERK2
by their protein and nucleic sequences. It is the case for all
mammals analyzed so far, for turtles in the reptilian clade and
for axolotl in amphibian clade. Among fishes, all teleost fishes
express two ERKs and it has been shown that the most ancient
branch of ray-finned fishes, the bichir, express ERK1 and ERK2.
Demonstration of ERK1 and ERK2 presence at this evolutionary
node is important since bichirs diverged from other vertebrates
prior to teleost fishes that underwent an additional WGD. Hence
ERK1 and ERK2 arose at least 400million years ago and studies of
ERK isoforms in fishes are relevant to mammalian ERK isoforms
since they arose from the same duplication event (Busca et al.,
2015). Further away in the vertebrate evolution tree, members
of all classes of cartilaginous fishes express only one ERK which
could be classified into the ERK2 group by three independent
topological methods used to infer the phylogeny. At the base
of vertebrates, hagfish and lampreys, belonging to the two most
divergent vertebrate species compared to mammals, also express
only one ERK isoform that is not possible to be classified as
ERK1 or ERK2. In all invertebrates studied so far, only one
ancestral ERK was identified; hence it is concluded that ERK1
and ERK2 arose from the earlyWGD at the base of the vertebrate
phylogenic tree (representation in Figure 1). From ray-finned
fishes to humans, ERK isoforms can be easily classified into ERK1
or ERK2 groups according to their coding sequences.
COMPARING STRUCTURES AND
REGULATION OF ERK ISOFORMS
Gene Structure
In vertebrates, erk2 gene is larger than erk1 gene, this is especially
obvious in mammals where erk1 genes are on average 15 fold
smaller than erk2 genes in the same animal (sizes calculated
from ATG initiating codon to stop codon; Busca et al., 2015).
The first intron of mammalian erk2 and the second intron of
drosophila erk are very large (59 kb and 25 kb respectively).
Clearly in drosphila, erk intron is among the largest ones, and
requires specific factors for proper splicing (Ashton-Beaucage
et al., 2010; Roignant and Treisman, 2010). These huge introns
could provide a unique regulation during development. This
point should be better understood in the future by genomic
truncation of the mouse erk2 gene’s first intron for example.
Alternative Splicing in the Coding
Sequence
R. Seger and his team reported that the intron 7 of several
mammalian ERK1s is not always spliced properly. In rat genome
the intron 7 sequence, if not spliced, is in phase with the coding
sequence of exons 7 and 8, thereby increasing the size of ERK1
by 26 amino-acids to a predicted protein size of 45.8 kD. Indeed,
a signal corresponding to a larger ERK protein has been detected
in rat IEC-6 cells by western blot (Boucher et al., 2004). These
ERK1 alternative splices were named ERK1b in rat and ERK1c
in human and chimpanzee. Human ERK1c predicted size is 40.1
kD instead of 43.1 kD for the normally spliced ERK1 since
non-splicing of intron 7 introducing a stop codon. Considering
isoforms functionality, it has been reported that ERK1c mediates
cell density-induced Golgi fragmentation (Aebersold et al., 2004).
It is tempting to wonder whether these alternative spliced
forms provide a ground to explain why ERK1 and ERK2 isoforms
have different functions and have been kept after the WGD.
We consider that this is very unlikely for several reasons. First,
ERK1b and ERK1c splice variants are expressed at very low
levels (Aebersold et al., 2004; Boucher et al., 2004); secondly it is
extremely puzzling that the sequence of intron 7 is not conserved
at all across species: non-spliced intron 7 truncates human ERK1
while it increases the size of rat ERK1. On one hand, it is striking
that the sequences of the correctly joined exons 7 and exon 8 are
extremely conserved in all mammals, including the monotreme
platypus which is phylogenically the most distant mammal to
humans (Figure 2A). On the contrary, even when restricting the
study to rodents, the protein sequences provided by intron 7 are
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FIGURE 1 | Expression of ERK proteins in animals. ERK1 and ERK2 proteins were classified as such upon phylogenic study of amino-acid coding sequences
(same conclusions were reached with nucleotide sequences; Busca et al., 2015).In invertebrates only one erk gene was identified so far. Ancestral ERK corresponds
to ERK protein sequence that cannot be classified into ERK1 or ERK2 group. Protein expression in vertebrate brains was described in the same study. Animal
silhouettes are from phylopic (http://phylopic.org/).
absolutely not conserved. The total lack of conserved protein
motifs renders the alternatively spliced ERK1s extremely unlikely
to play a function in the cell (Figure 2B). In rodents, for example
mouse ERK1b has a smaller molecular weight than mouse ERK1
(−0.67 kD) while rat ERK1b has a larger molecular weight than
rat ERK1 (+2.66 kD). Finally, in transgenic mice that express
only ERK1 cDNA (after disruption of all endogenous alleles of
erk1 and erk2), these splice variants do not exist, while mice live
and reproduce normally (Frémin et al., 2015). Therefore, this
alternative splices of ERK1 protein cannot provide a rationale for
a distinct function between ERK1 and ERK2 proteins.
Protein Sequences
Protein sequences of ERK1 and ERK2 are 84% identical in a given
mammal; human ERK1 is larger than human ERK2 due to an
extension of 17 amino-acids at its N-terminal and 2 amino-acids
at its C-terminal. The only described isoform-specific difference
leading to functional difference resides in the N-terminal of
mammalian ERK1. One report indicates that nuclear localization
of ERK1 is slower than that of ERK2 due to the 20 amino-acids
of ERK1 situated immediately after the poly-alanine stretch at N-
terminal end (Marchi et al., 2008). However, no mechanism that
could account for this difference has been reported so far, and
again mice expressing only ERK1 are perfectly viable and fertile;
hence this difference in rate of nuclear entry is not sufficient to
block normal regulation of ERK signaling.
Expression Levels of ERKs
ERK2 is expressed at higher levels than ERK1 in most
mammalian tissues (Busca et al., 2015; Frémin et al., 2015). One
origin of this difference resides on the strength of the proximal
promoters (1 kb upstream ATG codon), mouse erk2 promoters
being much stronger than mouse erk1 promoter in transiently
transfected NIH3T3 cells (Busca et al., 2015). However, the
difference of strength between mouse erk promoters is larger
than the steady state protein ratio measured (20% ERK1 and
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FIGURE 2 | erk1b RNAs from related species drive synthesis of unrelated proteins domains. Genomic sequences corresponding to exon7-intron7-exon8 of
MAPK3 (erk1) were retrieved from Ensembl release 83. First line: extension of the introns and exons, separated by vertical bars. “stop” indicates the final of ERK1 and
ERK1b coding sequences. Sequences were aligned by multalin program with identity matrix (Corpet, 1988). Alignments were performed also with Tcoffee and Clustal
Omega with the same results (not shown). Rat (Rattus norvegicus), guinea pig (Cavia porcellus), rabbit (Oryctolagus cuniculus), kangaroo-rat (Dipodomys ordii),
squirrel (Ictidomys tridecemlineatus), mouse (Mus musculus), platypus (Ornithorhynchus anatinus). Letters in red, amino-acids highly conserved for a position among
the protein sequences; letters in blue, amino-acids showing limited conservation; letters in black, amino-acids showing no conservation in the aligned sequences. (A)
The C-terminal sequences of rodents’ ERK1 proteins are highly conserved; platypus’ERK1 protein sequence is highly similar to rodents’ ERK1s. (B) Rodents’ ERK1b
proteins display no significant conserved protein motifs after exon7.
80% ERK2, Lefloch et al., 2008); therefore further research is
needed to understand the individual contribution of enhancers,
RNA regulation and protein stability to establish the final
ERK1/ERK2 protein ratio. One can note that mouse erk1 RNA
has only one short 3-prime UTR (632 bp) whereas mouse
ERK2 RNA has a long 3-prime UTR (3777 bp) displaying
also an alternative poly-adenylation site (transcripts mapk1-
001 and -002 from Ensembl release 83). Does this long 3-
prime UTR of ERK2mouse mRNA provide additional regulation
mechanisms? It is important to note that ERK expression is
elevated, calculated to be in the µM range by several authors
(reviewed in Fujioka et al., 2006). This concentration seems lower
than that of MEK but markedly higher than that of Raf. More
importantly, when proteomics measurements were performed
systematically in mouse NIH3T3 cells, it was shown that ERK2
is among the 400 most expressed cell proteins (twice more
expressed than PKA-catalytic subunit for example), and ERK1
is still among the 1500 most expressed cell proteins (10 fold
more than p70-S6K for example; Schwanhausser et al., 2011).
ERK protein expression is very stable and to our knowledge
no stimulus-induced variations of protein quantities have been
observed. The half-life of both ERK1 and ERK2 are very long,
being of 68 and 53 h respectively as determined by proteomics
analysis (Schwanhausser et al., 2011). ERK1 and ERK2 are
expressed at different levels and apart from a clear difference
in proximal promoter strength that was demonstrated recently,
more work is needed to understand the regulation of ERKs
protein expression.
Structural Changes upon Activation
The crystal structure of ERK2 protein was the second kinase
structure to be resolved after PKA catalytic subunit (Zhang
et al., 1994), at present many studies have described the crystal
structure of ERK1 and ERK2 when bound to partners and
small pharmacological inhibitors. Dual phosphorylation of ERK
triggers dramatic conformational changes within the activation
lip, reorganizing the substrate binding site to enable recognition
of the proline-directed phosphorylation motif of substrates (Pro-
X-pSer/pThr-Pro), and reorienting active site residues involved
in catalysis (Xiao et al., 2014). Side by side comparison of
ERK1 and ERK2 3D structures highlights their close homologies
(Ring et al., 2011). However, it was shown, by measuring
hydrogen/deuterium exchange, that constraints at the hinge
between the lobes of ERK2were released during activation, which
does not seem to be the case for ERK1 (Ring et al., 2011).
The functional consequences of this difference have not been
currently deciphered since both kinases dramatically increase
their catalytic activity upon phosphorylation.
Mechanism of ERKs Activation and
Substrate Recognition
ERK1 and ERK2 are simultaneously activated by the same
external growth factor agonists, indeed in vitro purified MEK1/2
can phosphorylate indiscriminately ERK1 and ERK2 (Robbins
et al., 1993). In fact close analysis of isoforms upstream in
the cascade failed to identify isoform-specific signaling cascades
Frontiers in Cell and Developmental Biology | www.frontiersin.org 6 June 2016 | Volume 4 | Article 53
Buscà et al. ERK1 and ERK2 are Functionally Redundant
(Lefloch et al., 2009). The ratio of active ERKs mimics exactly
the ratio of ERK proteins expressed in the cell, furthermore when
expression of one isoform is silenced, activation of the remaining
isoform is increased. Collectively these observations indicate that
MEK activates indistinctively ERK1 and ERK2 and that both
compete each other for the upstream activating kinase (Lefloch
et al., 2008). Both ERK1 and ERK2 were shown to translocate
to the nucleus upon stimulation (Lenormand et al., 1993).
Bacterially expressed ERK1 and ERK2 present similar specific
activities in vitro (Robbins et al., 1993), and previous works
of our group showed that this was also the case for immuno-
precipitated epitope-tagged ERK1 and ERK2 from HeLa cells
(Lefloch et al., 2008). These observations tend to indicate that
ERK1 and ERK2 phosphorylate their substrates with the same
efficiency, indeed it was shown that all the 284 interactors that
bind to ERK2 also bind to ERK1 (von Kriegsheim et al., 2009).
In addition, ERK1 and ERK2 share 22 out of 23 amino acids
that have been demonstrated to directly interact with substrates
(Lee et al., 2004; Liu et al., 2006), the sole difference being a
conservative substitution: leucine155ERK2 into isoleucine175ERK1
(Busca et al., 2015). Therefore, if we consider these data on
ERKs activationmechanisms and substrate recognition, nomajor
differences seem to exist between ERK1 and ERK2.
“Dimerization” Domains
Two decades ago Khokhlatchev et al. identified surface residues
that could interact to stabilize an ERK2-ERK2 dimer via studying
ERK2 crystals (Khokhlatchev et al., 1998). To assist in the
presentation of dimerization data in the literature we have drawn
a 3D image of ERK1 (from Protein Data Bank (Berman et al.,
2000) where the putative dimerization residues are highlighted
in yellow and gold (Figure 3) on structure 4QTB (Chaikuad
et al., 2014). These residues are located on the back of the kinase
with a group of four leucines and the sequence PE/DHD that
generates a protruding structure. ERK dimerization studies have
already been extensively reviewed (Lee and Bae, 2012; Roskoski,
2012). Here we will summarize our current understanding of
this process with an emphasis on differences among mammalian
ERK1s and ERK2s.
Several studies have failed to observe dimerization of ERK
molecules in cells. For example, studies from our group using
real time fluorescence microscopy and fluorescence correlation
spectroscopy failed to detect any dimer formation (Lidke et al.,
2010). Similarly, Burack and Shaw failed to demonstrate ERK2
dimerization in live cells through FRET measurements between
co-expressed yellow and cyan fluorescent ERK2s (Burack and
Shaw, 2005). By using gel filtration chromatography coupled
with multi-angle laser light scattering, Callaway et al. (2006)
revealed that histidine-tagged ERK2 is overwhelmingly present
as a monomer. Finally with an array of biochemical means,
Kaoud et al. have shown that ERK2 without any tag was strictly
monomeric, whereas only His-tagged ERK2 could partially form
a dimer (Kaoud et al., 2011). More recently, Herrero et al. have
reported that ERK2 from chicken embryo extracts does not form
dimers unlike ERK2 from mouse cells. Since ERK2s from these
two animals are over 99% identical (outside the alanine-rich N-
term that is highly variable among all ERKs) and share the same
“ERK-dimerization” domains it confirms that complex formation
depends on the cellular context (partners) but it does not depend
on the ERK2 protein itself (dimer formation).
The lack of ERK dimerization from these studies mentioned
above does not invalidate the initial observation of complex
formation and dimerization-mutants have proven to be very
instructive. For example we showed that dimermutant-ERK1
activation by MEK and its nuclear entry were delayed (Lidke
et al., 2010). Vomastek and co-workers have shown that
dimermutant-ERK2 failed to associate with the Trp protein, a
component of the nuclear pore (Vomastek et al., 2008). They
further demonstrated that Trp-ERK2 association did not use
classical ERK docking sites. More recently, Herrero et al. have
shown that ERK’s ability to form “dimers” was correlated to
PEA15 expression level (Herrero et al., 2015); PEA15 is a well-
known ERK partner (Formstecher et al., 2001). Even more
interestingly, they have identified a small molecule inhibitor
that blocks “dimerization” (it blocks the slower migration
of stimulated ERK in native PAGE electrophoresis; Herrero
et al., 2015). This inhibitor specifically blocked activation of
cytoplasmic ERK substrates and impeded tumorigenesis driven
by oncogenes of the RAS/ERK pathway and is the first of a new
class of inhibitors that targets interactions of ERK with partners
instead of blocking ERK activity. This inhibitor should also help
to understand the exact nature of the interaction between ERKs
and partner(s) via these “dimerization domains” (Herrero et al.,
2015).
Regarding differences between ERK isoforms, the four
leucines of the “dimerization” domain are conserved among
ERKs of all tetrapods. Therefore, they cannot provide grounds for
differences between ERK1 and ERK2. However, all mammalian
ERK1s share the PEHD sequence, whereas all mammalian ERK2s
have the sequence PDHD (the glutamic acid of ERK1 (E) is
highlighted in gold in Figure 3). Changing glutamic-acid for
aspartic-acid is considered a conserved substitution due to their
overall negative charge in solution, therefore via their PEHD
or PDHD sequences, ERK1s and ERK2s should bind similarly
to interactors. Nonetheless, glutamic acid is bulkier since it has
two carbon atoms on its side chain instead of one for aspartic-
acid. Therefore, mammalian ERK1smay display amore restricted
pattern of interactions with partners by requiring a deeper pocket
since these sequences generate protruding structures (Figure 3).
Interestingly, among all tetrapods, only ERK1s from squamates
(snakes, lizards, and geckos) have the aspartic acid at this
position. As we shall see later, these animals express only ERK1,
which could indicate that the PDHD sequence is more universal
than PEHD, being the sequence of tetrapods that express only
ERK1 (squamates) and all tetrapods’ERK2s, including animals
expressing only ERK2 (birds and frogs). However, invertebrates
have only one ancestral ERK that present either glutamic or
aspartic acid at this position, and even at the base of vertebrates,
lamprey’s only ERK has an aspartic acid whereas hagfish unique
ERK has a glutamic acid. Therefore, the structural difference,
PEHD in mammalian ERK1s vs. PDHD in mammalian ERK2s, is
likely to have minor consequences on interaction with partners.
Although, many studies have failed to show ERK
dimerization, the two “dimerization domains” play a role
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FIGURE 3 | Position of ERK “dimerization” domains on 3D representation of ERK1. The two domains of ERK implicated in “dimerization” are highlighted in
yellow on the 3D structure of ERK1 (still-images of structure 4QTB from RCSB PDB, www.rcsb.org, Chaikuad et al., 2014 viewed with CN3D software). “4 leucines” of
ERK1 are equivalent to leucines L333, L336, L341, and L344 of mouse ERK2 (Khokhlatchev et al., 1998). In the sequence PEHD (equivalent to P174DHD177 of
mouse ERK2), the glutamic acid of mammalian ERK1s is highlighted in gold. On mammalian ERK2s this glutamic-acid is replaced by an aspartic acid that is less bulky.
in ERK response. The minor structural differences between
ERK1 and ERK2 in the PE/DHD domain may trigger minor
signaling differences that may be uncovered when partners that
assemble with ERK via this domain will be fully identified.
SEARCH FOR SPECIFIC FUNCTIONS OF
ERK ISOFORMS
Upstream of ERK in the signaling cascade, clear functional
differences among isoforms have been demonstrated. For
example, at the Raf level, B-Raf displays a greater specific activity
than A-Raf and C-Raf, and partners of Raf kinases vary greatly
(Desideri et al., 2015). Indeed B-Raf is already primed for MEK
activation via constitutive phosphorylation of Ser445 and amino-
acids negatively charged that mimic the phosphorylation status
observed in activated A-Raf or C-Raf isoforms (Asp448 in B-Raf)
(Tran et al., 2005). At the level of MEK1 and MEK2, only MEK1
can be regulated by multiple phosphorylation of its proline-rich
domain. MEK1 can be retro-phosphorylated by ERK (Saito et al.,
1994) in the context of phosphorylation by PAK kinase that
transmits signaling from the cell matrix (Eblen et al., 2004).
Clear differences in the pattern of tissue-specific expression
among isoforms as also been demonstrated upstream of ERK. For
example, B-Raf has been described to be more expressed in cells
of neuronal origin (Storm et al., 1990) and MEK2 was shown to
be preferentially expressed in embryos and excluded from adult
brains (Alessandrini et al., 1997; Di Benedetto et al., 2007). Taken
together, all these observations indicate that the role of individual
isoforms can be unique in the pathway; therefore the quest to
understand putative functional differences between ERK1 and
ERK2 is relevant to further understand all regulatory aspects of
this signaling cascade.
In order to seek for specific ERK1 and ERK2 functions, their
respective expression levels have been reduced by distinct means
and phenotypical consequences have been analyzed. Expression
of ERK1 and/or ERK2 has been silenced via expression of
morpholinos in zebrafish, shRNA/siRNAs in cultured cells or
disrupted by gene knock-out in mice. Since ERK1 and ERK2
proteins are usually not expressed at the same level, it is very
important to take into account the relative level of both proteins
to interpret the data. We want to emphasize that only the
dual phosphorylated and activated forms of ERK1 and ERK2
define a common conserved epitope recognized by the same
anti-phospho antibody (Busca et al., 2015). Indeed, the direct
relationship between the ratio of phosphorylated ERKs and the
quantitative expression ratio of ERKs has been previously shown
(Lefloch et al., 2008), therefore the easiest way to evaluate the
ratio between ERK1 and ERK2 in a biological sample consists
in measuring the ratio between the dually-phosphorylated ERK
isoforms. Ideally it would be of interest to add-back either
isoform by recombinant vectors; unfortunately it is difficult
to express successfully ERK cDNAs that can be activated as
efficiently as the endogenous ERK. Usually a smaller proportion
of transfected ERK is activated compared to endogenous protein
(one example is found in Figure 6 of Radtke et al., 2013).
Morpholinos
Morpholinos (modified antisense oligo-nucleotides that are
biologically stable) have been injected into zebrafish embryos
to assess the contributions of ERK1 and ERK2 during zebrafish
development. From the same laboratory, one study concluded
that ERK1 and ERK2 target common and distinct gene sets
during embryogenesis (Krens et al., 2008a) while another study
concluded that cell migration defects during gastrulation were
more pronounced upon ERK2 knock-down (Krens et al., 2008b).
In this latter publication the authors indicate that morpholinos-
mediated knock-down of ERKs could be rescued by co-injection
of the corresponding mRNA. Strikingly, erk2 mRNA cross-
rescued ERK1 knockdown, but erk1mRNA was unable to rescue
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ERK2 knockdown. These results tend to indicate that ERK1 and
ERK2 play different roles in zebrafish development. A close look
of the data reveals that ERK2 morpholinos reduce markedly
more the global level of phospho-ERK than ERK1 morpholinos
(measured by immuno-histochemistry with anti-phospho ERK
antibody at 4.5 and 8 h post fertilization, Figure 6 in Krens et al.,
2008b). Furthermore, when evaluating the expression level of six
genes at 4.5 h post fertilization (goosecoid; antivin; vox; vent;
notail; tbx6), injection of morpholinos targeting ERK1 reduced
mildly the level of 5 genes, whereas morpholinos targeting ERK2
reduced strongly the level of all genes (Figure 10 in Krens
et al., 2008a). Taken together, these two observations seem to
indicate that ERK2 is more expressed than ERK1 in zebrafish
embryos, consequently the different outcome observed when
reducing ERK1 or ERK2 quantity could be linked to their
different effectiveness to reduce global ERK activity, not due
to isoform-specific functions. Injection of erk1 RNA did not
rescue anti-ERK2 morpholinos, whereas the opposite situation
was effective. However, in this study no data indicate that erk1
RNA re-established a normal level of global phospho-ERKs to
conclude unambiguously an ERK1-specific effect.
Silencing by siRNA and shRNAs
Knock-down of ERK isoforms using specific siRNAs has been
used in several studies to replace chemical inhibitors that inhibit
ERK activity in cells. For example, in two lines of ovarian-
cancers cells (HeyC2 and KGN), simultaneous diminution of
ERK1 and ERK2 by a pool of siRNA was shown to reduce cell
proliferation more effectively than MEK inhibition by either one
of two chemical inhibitors (PD98059 and U0126; Steinmetz et al.,
2004).
At least 27 publications have evaluated the role of individual
ERK isoforms in biological processes via siRNAmediated knock-
downs, and 4 more publications have combined the expression of
shRNA directed to ERK2 with genomic erk1 gene knock-out. It
must be noted that removal of ERK1 alone induced phenotypical
changes in 13 studies (Table 1); we can therefore conclude that
ERK1 plays significant roles in many mammalian tissues that can
be compensated in ERK1−/− animals. The fact that ERK1 has a
functional role in mammals can also be deduced from the high
stability of ERK1 protein sequence during evolution (Busca et al.,
2015), if ERK1 had been dispensable its sequence would have
derived rapidly.
ERK1-Specific Effects
Two studies have concluded that reduction of ERK1 expression
was effective to induce phenotypes whereas reducing ERK2
expression was ineffective. In the study of Jung et al. the authors
tested the role of ERK isoforms on the action of cordycepin
on vascular smooth muscle cells (VSMC) (Jung et al., 2012).
In VSMC, cordycepin increases the levels of p27KIP1 while it
reduces both CDK4 levels and cell proliferation. These three
actions of cordycepin were reversed by transfection of a single
siRNA targeting ERK1 but not by a siRNA targeting ERK2. In
these cells, the expression levels of ERK1 and ERK2 appeared very
similar, or slightly higher for ERK2, if we look at the presented
phospho-ERK immuno-blots. Unfortunately, the effectiveness of
each siRNA to reduce the protein level of its target was not shown;
hence it is not possible to correlate the decrease of global active
ERK by the siRNAs with the phenotypical consequences. In the
study of Bae et al. (2013), a single siRNA was also used against
each ERK, and the effectiveness of each siRNAs to reduce ERKs
levels was not presented, nor was shown the effectiveness of each
siRNA to reduce the global active ERK levels. The authors claim
that only transfection of siRNA targeting ERK1 reduced the IGF-
1 mediated induction of two mucin genes, in NCIH292 airway
epithelial cells (Bae et al., 2013). Altogether, the lack of controls in
these two publications impairs concluding that only the decrease
of ERK1 expression can trigger specific phenotypes (Jung et al.,
2012; Bae et al., 2013).
Different Effects upon Silencing ERK1 or ERK2
Three publications propose different outcomes after knocking-
down of ERK1 vs. ERK2 (one that will be discussed in
the following paragraph on hepatocytes). In rhesus fibroblasts
infected with rhadinovirus, Woodson and Kedes. conclude that
knock-down of ERK1 seems to increase viral production whereas
ERK2 accumulates preferentially into viral particles (respectively
Figures 9, 10 in Woodson and Kedes, 2012). In these cells ERK2
is much more expressed than ERK1 as determined by phospho-
ERK levels (Figure 6A of Woodson and Kedes, 2012) and in
reality ERK2 does not accumulates preferentially in virions since
the authors state in the caption of their Figure 8 that “intravirion
ERK content reflects intracellular expression of ERK isoforms”.
Further, of concerns for interpreting the data in Figure 8 of
Woodson and Kedes (2012), the total-ERK and phospho-ERK
blots have been inverted.
In a study regarding human epithelioid malignant
mesotheliomas (Shukla et al., 2011), the authors propose
that ERK1 and ERK2 play different functions on the ground that
gene expression is altered differently in stable clones expressing
less ERK1 vs. stable clones expressing less ERK2. Unfortunately
one cannot find measurement of the relative level of ERK1 and
ERK2 since no phospho-specific antibodies were used, and this
makes the interpretation of the data very difficult. Could their
results be simply due to different contributions of ERK1 and
ERK2 to global ERK activity? (Shukla et al., 2011).
ERK2-Specific Effects
In hepatocytes
Fourteen publications state that ERK2 silencing triggers
biological consequences whereas ERK1 silencing does not.
Among these studies, several were performed in hepatocytes
with contrasting results that we have attempted to analyze. At
first glance, in most experiments hepatocytes seem to express
equivalent levels of ERK1 and ERK2, an ideal situation to
compare the contribution of these isoforms to conduct ERK
signaling. However, a closer look at the data reveals that it is
clearly not the case in all hepatocytes cultures; for example
in hepatocytes from a publication of Figure 3 in Frémin
et al. (2009) there is clearly much more ERK2 than ERK1
(similarly in stellar HSC-T6 cells from the study of Figure 1C
in Zhong et al., 2009). In a single publication, the ERK1/ERK2
ratio seems to vary between experiments and the reason for
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TABLE 1 | Overview of studies using shRNA or siRNA transfections to study ERK1 vs. ERK2 signaling.
References ERK1/2 ratio Effect on phospho-ERKs Cell line Phenotypes studied
PHENOTYPES ONLY ERK1-DEPENDENT
Zhong et al., 2009 E1 ≥ E2 Yes Rat hepatic stellate HSC-T6 Cell proliferation, gene induction, hepatic fibrosis
Jung et al., 2012 E2 ≥ E1 Not done Rat vascular smooth muscle cells Cordycepin dependant block of cell proliferation
Bae et al., 2013 E2 > E1 Not done Human pulmonary NCI-H292 IGF1-dependant MUC8 and MUC5B induction
PHENOTYPES ONLY ERK2-DEPENDENT
Vantaggiato et al., 2006 E2 > E1 yes Mouse embryo fibroblasts +
NIH3T3
Cell proliferation, colony and tumor formation
Li and Johnson, 2006 E2 > E1 Yes Mouse myoblasts C2C12 Myoblast proliferation and differentiation
Wille et al., 2007 E2 > E1 Yes Hybridoma 1B6 T IL-2 production from TCR stimulation
Bessard et al., 2008 E2 > E1 Yes Rat hepatoma cell line, rat biliary
epithel.
Hepatocytes proliferation
Carcamo-Orive et al.,
2008
E2 > E1 Not done Human mesenchymal stem cells Proliferation and adipogenic differentiation
Li et al., 2009 E2 > E1 Yes Mouse NIH3T3 TGF-beta1-induced collagen synthesis
Shin et al., 2010 E2 > E1 Not done Human mammary gland MCF-10A Epithelial-to-mesenchymal transformation
Botta et al., 2012 Not done Not done H. pancreatic ductal epithelial cells Cell invasion, MMP RNA increase
Lee et al., 2013 E2 > E1 Yes Human HSC-3 and MDA-MB-231 Expression of tumor-derived G-CSF
Radtke et al., 2013 E2 > E1 Yes H. non-small cell lung carcinoma
A549
HGF-induced cell motility, paxillin phosphorylation
Shin et al., 2013 E2 > E1 Yes Mouse embryo fibroblasts Increase p19mArf and p16Ink4a, senescence
Bonito et al., 2014 E2 > E1 Yes Human osteosarcoma cells U2OS Expression of cytokine receptor sub-unit gp130
Gusenbauer et al., 2015 E2 > E1 Not done H. squamous carcinoma cell SCC9 Amphiregulin upregulation by HGF
Chang et al., 2015 E2 > E1 Not done H. monocytic leukemia cell line
THP-1
LPS-induced G-CSF
PHENOTYPES ERK1 and ERK2-DEPENDENT
Zeng et al., 2005 E2 > E1 Yes Human ovarian epithelium pOSE Cell viability
Lefloch et al., 2008 E2 > E1 Yes Mouse NIH3T3 Cell proliferation
Wei et al., 2010 Not done Not done Human breast MCF7 Etoposide-induced G2/M arrest, ATM pathway
Wang et al., 2011 E2 > E1 Yes Human chondrocytes Osteoarthritis/cartilage breakdown
Wei et al., 2011 E1 = E2 Not done Human breast MCF7 Hydroxy-urea induced DNA damage response
Shukla et al., 2011 Not done Not done Human mesotheliomas HMESO Cell proliferation, migration and tumor growth
Woodson and Kedes,
2012
E2 > E1 Yes Rhesus monkey fibroblasts RRV virus production and localization inside virion
Qin et al., 2012 E2 > E1 Yes Human A375 melanoma cells Cell proliferation and cell death
Frémin et al., 2012 E2 ≥ E1 Yes Rat hepatocytes Survival, proliferation, differentiation state
Zhu et al., 2015 E2>E1 Yes H. rhabdomyosarcoma RD Enterovirus (EV71) replication
shRNA MEDIATED SILENCINGS AND erk1 GENE DISRUPTION
Fremin et al., 2007 E1 = E2 Yes Primary murine hepatocytes Cell proliferation
Frémin et al., 2009 E2 ≥ E1 Yes Primary rat hepatocytes Cell proliferation and survival
Voisin et al., 2010 E1 ≥ E2 Yes Mouse embryo fibroblasts Cell proliferation
Guegan et al., 2013 E2 > E1 Yes H. hepatocellular carcinoma cells
Huh-7
Cisplatin-induced cell death
“ERK1/2 ratio” (2nd column) was determined indirectly from western-blots probed with anti-phospho-ERK antibodies revealing active ERK levels, as demonstrated previously (Lefloch
et al., 2008). “Effect on phospho-ERKs” (3rd column) indicates whether or not the impact of shRNAs or siRNAs on phospho-ERKs levels was evaluated by western-blot. Only the main
phenotypes studied are presented (last column).
these changes is not explained. One explanation could be
the very low level of active ERKs in most of the hepatocytes
preparation, a low level that magnifies the background from
antibodies that have some weak affinity for mono or even
non-phosphorylated forms of ERKs. This situation has been
encountered by Jung et al. in vascular smooth muscle cells,
in cells where global ERK activity is elevated the immunoblot
reveals much more phospho-ERK2 than phospho-ERK1 (Figure
4A in Jung et al., 2012); whereas there was not much difference
between phospho-ERK1/ERK2 in the blot of their Figure 4B
when ERK activity was much lower. The same conclusion can
be drawn from Figure 1A in a study from Steinmetz et al.
(2004), where extracts from the same cell line are loaded side
by side, only the extracts with high level of phospho-ERK
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demonstrate the clear prevalence of ERK2 (Steinmetz et al.,
2004).
Furthermore, in hepatocytes it was shown for the first time
that following ERK1 or ERK2 decrease, the remaining isoform
was over-activated up to 11 fold (Fremin et al., 2007). Therefore,
the global strength of ERK activation following removal of ERK1
or ERK2 needs to be measured, which is usually difficult to do
when the activation levels are low, as it seems to be the case in
most hepatocytes preparations. A clear example of this problem
is shown in Figure 6D from a study by Frémin et al. (2012) where
global phospho ERK seemed to be increased upon knock-down of
ERK1 due to increased intensity of phospho-ERK2 band. Indeed,
opposite consequences on phenotypes have been found; for
example Zhong et al. (2009) have shown that decrease of ERK1
suppressed hepatic fibrosis and reduced cell proliferation. On the
contrary Frémin et al. have concluded that only ERK2 silencing
reduced hepatocytes proliferation (Fremin et al., 2007). In a
later study, these authors have shown that ERK1 silencing could
enhance hepatocyte survival (Frémin et al., 2009). More recently
it has been shown that dual silencing of both ERK1 and ERK2 is
required to maintain a highly differentiated state of hepatocytes,
while survival and proliferation was suggested to be regulated via
a complex interplay between ERK1 and ERK2 functions (Frémin
et al., 2012). Similarly the fate of PC12 cells toward proliferation
or differentiation was shown to be dependent on the strength
and duration of ERK signaling, therefore a precise knowledge
of the global level of active ERK is required all along these long
lasting processes, to be able to effectively assign a function to
ERK1 vs. ERK2 isoforms (Dikic et al., 1994; Traverse et al., 1994).
Even small differences in ERK1/ERK2 expression level could
be translated into differences of global ERK level, leading into
different phenotypical consequences.
ERK2-specific effects in other cell lines
Twelve studies, independent of those using hepatocytes, have
revealed phenotypes induced only by ERK2 decrease, it is
essential to note that in 11 of them, cells express markedly more
ERK2 which by itself could provide an explanation for the lack
of effect of ERK1 knock down as demonstrated previously in
NIH3T3 cells (Lefloch et al., 2008). In the last study out, the
ratio cannot be determined by lack of phospho-ERK immunoblot
(Botta et al., 2012).
In the studies of Chang et al. (2015), Gusenbauer et al.
(2015), and Carcamo-Orive et al. (2008) unfortunately the
effectiveness of siRNAs to reduce global ERK activation is not
demonstrated, impeding to draw conclusions. Bonito et al.
(2014) report that differences between both ERKs knock-down
could not be attributed to quantitative differences because
they extend their work to MCF7 cells which they claim to
express the same level of ERK1 and ERK2. This remains to
be demonstrated unambiguously, since unfortunately they did
not measure phospho-ERK levels in those cells; furthermore the
effect of ERK2 silencing triggered only a 30–40% diminution of
GP130 expression, therefore a 10–20% decrease that could be
caused by ERK1 silencing (if ERK1 was slightly less expressed
than ERK2), would be difficult to demonstrate. Most of their
conclusions were drawn from cell lines expressing markedly
more ERK2 than ERK1 (Bonito et al., 2014). Finally, the studies
of Li and Johnson (2006), Shin et al. (2013), and Li et al. (2009)
have shown that only ERK2 silencing markedly reduces global
ERK activity, providing a direct explanation for the lack of
consequences after ERK1 knock-down.
Studies proposing ERK2-specific roles from add-back
strategies
In MCF-10A breast cancer cells, Shin and co-workers elegantly
demonstrate that the epithelium-mesenchymal transition is
dependent on ERK activity via interaction with substrates
containing DEF docking sites (Shin et al., 2010). However,
these authors did not assess the effectiveness of the shRNAs to
decrease global ERK activity, nor did they present the capacity
of transfected ERK isoforms to re-establish the global ERK
activity after knock-down. Direct comparison of ERK1 vs. ERK2
expression from transfected plasmids is rendered complicated by
the use of different tags in ERK1 and ERK2 (measurement of
expression with total ERK antibody could introduce an isoform-
bias as discussed above). Furthermore, Figure S4 in Shin et al.
(2010) reveals that ERK2 is much more expressed than ERK1
in those cells, which could explain why only ERK2 silencing
impeded epithelio-mesenchymal transition. Vantaggiato and co-
workers have also transfected ERK isoforms and showed that
ERK1 expression was able to block Ras-induced increase of
colony formation in contrast to transfected ERK2, however the
size of transfected ERK1 is abnormally smaller than that of ERK2,
rendering difficult the interpretation of the results (Vantaggiato
et al., 2006). These authors have also shown that removal of
ERK1 in a stable line of mouse embryo fibroblasts (MEFs)
accelerates the rate of cell proliferation whereas removal of ERK2
decreases this parameter. This observation is surprising, first
because the ERK1 removal in MEFs was demonstrated by others
to slow cell proliferation (in five MEFs preparations of early
cell culture passages; Voisin et al., 2010), and second because
mice over-expressing ERK1 live and reproduce normally, even
in the total absence of ERK2 protein (Frémin et al., 2015).
Indeed Voisin et al. have demonstrated that individual loss
of either ERK1 or ERK2 slows down the proliferation rate of
fibroblasts to an extent reflecting the expression level of the
kinases (Voisin et al., 2010). In A549 lung carcinoma cells, Radtke
et al. (2013) concluded that only ERK2 mediates HGF-induced
motility. In these cells ERK2 is markedly more expressed than
ERK1, and in Figure 5A of the paper only shERK2 is shown
to reduce global ERK activity which could explain why only an
ERK2-mediated effect was observed. In an add-back experiment
(Figure 6 in Radtke et al., 2013) HA-tagged ERK proteins are
hugely expressed and furthermore only transfected HA-ERK2
was markedly stimulated upon HGF treatment. This can explain
again why only ERK2 mediates the action of HGF (Radtke et al.,
2013).
One well controlled study reporting ERK2-specific effect
In HSC-3 cells, Lee et al. report that a decrease in ERK1
expression reduces more effectively global ERK activity than
ERK2 decrease, but only ERK2 knockdown reduces G-CSF
mRNA levels (Figure 5 in Lee et al., 2013). For the first time,
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this study clearly favors a distinct role for ERK isoforms, however
in the same study with another cell line (MDA-MB-231) the
same authors report a direct correlation between the global ERK
activation (reduced significantly only by ERK2 knockdown) and
G-CSF mRNA levels.
Redundant Effects
If we consider the remaining 10 studies that report a biological
consequence after reducing ERK1 quantity, all of them have also
revealed a specific phenotype upon ERK2 protein diminution.
Most of these studies (7 out of 10) reveal a redundant role of both
ERK isoforms. Unfortunately, for the study of Zeng et al. (2005)
(siRNAs in cancerous ovarian cells) and for two publications
from the group of D. Tang (siRNA in MCF7 cells, Wei et al.,
2010, 2011) the decrease in phospho-ERKs was not measured,
rendering impossible to correlate the higher effectiveness of
ERK1 knock-down to a slower ovarian cell proliferation for
example. Surprisingly the same blot was used in both papers from
the group of D. Tang to illustrate the effectiveness of each shRNA
to reduce expression of their targets.
Fortunately several publications have presented the
effectiveness of knock-downs to regulate global ERK activity,
allowing to correctly interpreting the data. For example, the
production of EV71 viral particles in Rhabdomyoscarcoma cells
was shown to be equally diminished by reduction of ERK1 or
ERK2 expression (Zhu et al., 2015). Here, both siRNAs effectively
reduced the global level of active ERKs, despite the fact that these
cells seem to express more ERK2. Pharmacological inhibition of
MEK activity by U0126 inhibitor was more effective to reduce
global ERK phosphorylation level, and was shown to further
reduce the production of viral particles (Zhu et al., 2015). In
human melanoma cell line A375, Qin et al. have shown that
silencing of ERK1 or ERK2 reduces the levels of active ERK
and killed the cells by similar apoptosis induction. Silencing
of ERK isoform was performed with lentiviral particles that
express shRNAs. Interestingly enough, ERK1 silencing was
sufficient to reduce the global levels of active ERK, although
the expression level of ERK1 is somewhat lower than that of
ERK2 in these cells (Qin et al., 2012). In human chondrocytes
infected with lentivirus expressing shRNA, Wang et al. (2011)
showed that knock-down of either ERK1 orERK2 reduces the
mRNA levels of MMP3 and MMP13 and type II collagen, while
double knock-down of ERK1 and ERK2 acted synergistically.
Furthermore, there is a correlation between the effectiveness of
the shRNAs to reduce the global levels of active ERK and the
consequences on MMPs and collagen II expression.
Conclusions from Studies with siRNAs and shRNAs
Overall nearly all publications claiming a specific role of ERK2
can be re-interpreted by observing that higher reduction of global
ERK activity upon ERK2 silencing induces more effects than
upon ERK1 silencing. Doubts persist only in studies that cannot
be carefully interpreted by lack of assessment of the contribution
of each isoform to the global ERK activity. Only in one out of
two cell lines of the study of Lee et al. (2013) was demonstrated
an ERK2-specific effect. In the few cell lines studied that express
more ERK1 than ERK2, ERK1 was demonstrated to be the pre-
eminent isoform driving defined phenotypes. Therefore, in all but
one study, the observed phenotype develops proportionally to the
reduction of the global ERK activity.
Of special interest is the work of Wille et al. who used
stable expression of shRNA targeting ERK1 or ERK2. The
stable clones generated expressed various levels of shRNAs,
producing a quantitative range of knock-downs in mouse
1B6 hybridoma cells (Wille et al., 2007). These authors
demonstrate a strict correlation between global ERK activity and
a signal output (IL-2 production) irrespective of the targeted
isoform.
Similarly, in NIH3T3 it has been demonstrated that ERK1
knock-down decreases cell proliferation only when ERK2 is
lowered at the same time to a threshold level. In these
NIH3T3 fibroblasts, ERK activity is mainly provided by the
ERK2 isoform that represents 80% of the total ERK pool
(Lefloch et al., 2008). Globally, experiments knocking-down
ERK1 and ERK2 by siRNAs and shRNAs converge to reveal
that ERK1 and ERK2 contribute to ERK signaling according
to their contribution to global ERK activation; therefore
suggesting their functional redundancy at least for the read-out
reported.
erk1, erk2 Gene Disruption
Several studies have tried to uncover functional differences
between ERK1 and ERK2 by gene knock out in mice. Mouse
ERK1 was disrupted by removal of exon 3 (Pages et al., 1999).
ERK1−/− animals lived and reproduced normally in striking
contrast to erk2 disruption that led to early embryonic death
(Hatano et al., 2003; Saba-El-Leil et al., 2003; Yao et al., 2003). The
opposite fates of ERK1 vs. ERK2 invalidations initiated the quest
to discover whether these two conserved kinases play distinct
roles. Lack of ERK2 led to placental failure that could account for
the early lethality (Hatano et al., 2003; Saba-El-Leil et al., 2003).
When the placental defect was rescued by tetraploid-aggregation,
ERK2-deficient fetus grew as well as littermate controls for 5
more days, up to E13.5 (Hatano et al., 2003), however this rescue
did not allow animals to be born alive. To remove the possibility
that lethality was due to a delayed placental failure, the group of
Meloche has recently shown that erk2 disruption in the epiblast
still led to lethality (they induced a CRE-dependent ERK2 knock-
out in the whole embryo except placenta; Frémin et al., 2015).
Indeed in a different mouse genetic background, it was shown
that erk2 disruption did not form mesoderm (Yao et al., 2003).
Overall, ERK2 is absolutely required for mammal life at several
stages of development. In adult mice already lacking ERK1,
inducible invalidation of ERK2 led to death by multiple organ
failures within weeks (Blasco et al., 2011).
In order to correctly interpret the data from genomic
disruptions of ERK isoforms, one should at least analyze the
contribution of ERK1 and ERK2 to the global ERK activity
in wild-type tissues. Ideally total ERK activity of tissues from
wild-type animals should be compared with tissues from mice
lacking one ERK isoform, since lack of one isoform is partially
compensated by over-activation of the remaining one.
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erk1 Disruption
At least 17 studies describe consequences of ERK1 sole removal
in mice. ERK1 being less expressed than ERK2 in most mouse
tissues (Frémin et al., 2015), phenotypes are usually not dramatic
and great care needs to be taken to interpret the data. For
example it was initially reported that lack of ERK1 impeded
terminal differentiation of CD4CD8 thymocytes (Pages et al.,
1999), however studies with congenic mice (different genotypes
in the same litter) led to conclude that thymocytes proliferate
and differentiate normally in mice lacking ERK1 (Fischer et al.,
2005; Nekrasova et al., 2005). Goplen and co-workers have shown
by western-blot analysis that the lack of ERK1 decreased by
half the global ERK activity in airway tissues thereby impairing
mice lacking ERK1 to develop airway inflammation and hyper-
reactivity to experimental asthma (Goplen et al., 2012). Table 2
illustrates the multiple phenotypes observed in mice lacking
ERK1, such as resistance to obesity (Bost et al., 2005), increase
in long-term memory (Mazzucchelli et al., 2002) and hyper-
activity in open field (Selcher et al., 2001). Considering these
multiple studies, although mice lacking ERK1 live and reproduce
normally, ERK1 is an essential kinase which role is can be
revealed upon challenging the ERK pathway. For example, mice
lacking ERK1 develop less skin papilloma generated by DMBA
and TPA treatment than wild-type mice (Bourcier et al., 2006).
erk2 Disruption
Since the absence of ERK2 without artificial compensation
is lethal for mice, hemizygote disruption (ERK2+/−) and
hypomorphic mice were generated. The hypomorphic animals
expressed about 20–40% less ERK2 than wild-type ones due
to insertion of the neomycin resistance cassette in the 5-prime
region of the erk2 gene (Satoh et al., 2007). The mere presence of
the neo cassette reduced ERK2 expression, but unfortunately the
active ERK levels were not presented in this study. Nonetheless,
gene dosage was indirectly demonstrated since it was impossible
to generate an animal expressing only a single hypomorphic allele
of ERK2 whereas a smaller increment in ERK2 expression via a
single wild-type ERK2 allele was sufficient to sustain life (Satoh
et al., 2007). Spatial working memory was normal in animals
expressing less ERK2, however mutant mice showed a deficit in
long-term memory in classical fear conditioning (Satoh et al.,
2007). Lips et al. compared hemizygote disruption of ERK2 with
total disruption of ERK1 in ischemic injury studies. Global ERK
was immuno-precipitated from ERK2+/− and ERK1−/− hearts
to measure kinase activity on MBP substrate (Lips et al., 2004).
Mice lacking both alleles of ERK1 or only one allele of ERK2
presented very similar levels of ERK activity in hearts as observed
in the western blots presented, however these authors claim
that only ERK2+/− mice presented an increased infart area in
heart after ischemic injury. The infart surface represented the
30% of the heart in WT mice and it increased up to the 40%
ERK2+/− mice. Considering that mouse hearts express more
ERK2 than ERK1 in their study, they may have missed a small
difference in ERK immuno-precipitated kinase activity that could
explain the lack of statistically significant effect in ERK1−/− mice
compared to the mild effect in ERK2+/− (Lips et al., 2004). In
an independent study from the same laboratory, neither mice
lacking both alleles of ERK1 nor mice lacking one allele of
ERK2 showed a reduction in pathologic or physiologic stimulus-
induced cardiac growth (Purcell et al., 2007). In that study, the
impact of gene disruption on phospho-ERK level was negligible
and could explain this lack of effect (Figure 1B of Purcell et al.,
2007). However, expression of the phosphatase DUSP6 reduced
markedly ERK activity in the heart and predisposed mice to heart
decompensation and failure (Purcell et al., 2007).
Chen and co-workers have invalided erk1 and erk2 genes
in mouse embryonic stem cells (ESCs) by Talen or Crisp/Cas9
technologies (Chen H. et al., 2015) (respectively Transcription
Activator-Like Effector Nucleases and Clustered Regularly
Interspaced Short Palindromic Repeats). These authors
established readily erk1−/− and erk2−/− cells. However,
double disruption of erk1 and erk2 genes was impossible unless
ERK1 expression was induced from a cDNA stably integrated.
MEK inhibition by small chemical inhibitors is known to
promote self-renewal of embryonic stem cells, here ERK
expression irrespective of the isoform, and ERK kinase activity
were demonstrated to be necessary for ES-cells self-renewal and
genomic stability (Chen H. et al., 2015).
Tissue Specific erk2 Disruption
Tissue specific disruption of erk2 is necessary to bypass early
embryonic lethality. For this purpose exon 3 of ERK2 was
surrounded by two loxP sites, and upon expression of the Cre
recombinase, exon 3 was deleted to generate a non-functional
ERK2 protein (Fischer et al., 2005). Lines of mice expressing Cre
recombinase in a tissue at a specific stage of development were
crossed with mice harboring ERK2 gene with loxP sites on each
side of exon 3 (in Table 2mice are listed by the promotor driving
Cre expression, which defines the cells were recombination
occurs). Alternatively, the recombinase can be ubiquitously
expressed, but its expression can be pharmacologically switched
on. For example tamoxifen has been shown to activate CRE in a
timely fashion in Cre-ERT2 mice. Indeed, in adult Cre induction
by tamoxifphen led to death by multiple organ failures upon
deletion of ERK2 in mice already lacking ERK1 constitutively
(Blasco et al., 2011). Finally, Cre recombinase can be expressed
by viral infection of airway cells with adenoviruses encoding Cre
(Blasco et al., 2011).
Out of 19 publications presenting tissue-specific disruption of
erk2, we shall limit our detailed analysis to the 4 studies where
ERK1 was shown to be more expressed than ERK2 in targeted
cells, and the 5 studies where ERK2 was shown to be more
expressed than ERK1 (ratio evaluated by western-blot displaying
phospho-ERK levels, Table 2). In other publications, the
expression ratio between isoforms cannot be evaluated, impeding
proper isoform-assignment to the observed phenotypes.
Among cells expressing somewhat more ERK1, Blasco et al.
indicate that lung tumor development driven by K-RasG12V is
not impaired upon invalidation of a single isoform; however
disruption of both ERK1 and ERK2 appears necessary to block
tumor progression (Blasco et al., 2011). Richardson et al. describe
that macrophages can proliferate and differentiate by expressing
either ERK1 or ERK2. In mice expressing ERK1, removal of
erk2 gene by Cre-recombinase does not change the profile
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TABLE 2 | Overview of studies using genomic disruption to study ERK1 vs. ERK2 signaling.
Refernces ERK1/2 ratio Effect on
phospho-ERKs
Promoter of Cre recombinase Main phenotypes
erk1 GENE DISRUPTION IN WHOLE MICE
Pages et al., 1999 E2 > E1 Yes Thymocytes differentiation
Selcher et al., 2001 E1 = E2 Yes Behavior, activity in the open field, fear,
learning, fear acquisition
Mazzucchelli et al., 2002 E2 > E1 Yes Long-term memory, rewarding properties of
morphine
Nekrasova et al., 2005 Variable Yes Thymocytes differenciation, priming
encephalomyelitis
Bost et al., 2005 E1 = E2 Not done Adipose tissue development, obesity and
insulin resistance
Agrawal et al., 2006 not done Not done Thymocytes Th1 polarization, immune
response, encephalomyelitis
Ferguson et al., 2006 Not done Not done Psychomotor sensitization to cocaine,
behavioral plasticity
Cestari et al., 2006 Not done Not done Memory reconsolidation, fear conditioning
Bourcier et al., 2006 E2 > E1 Yes/No Cutaneous lesions, TPA+DMBA induction of
skin papillomas
Nakazawa et al., 2008 E2 > E1 Yes NMDA-induced retinal injury
Alter et al., 2010 E2 > E1 Yes Formalin-induced long-term heat
hypersensitivity, pain models
Lee et al., 2010 E2 > E1 Yes Adiposity and adipogenesis, insulin resistance
Cisse et al., 2011 Not done Not done Secretion of N1 fragment of cellular prion
protein PrP(c)
Jager et al., 2011 Not done Not done Obesity, insulin resistance, liver steatosis,
glucose uptake
Saulnier et al., 2012 Not done Not done Osteopetrosis, differentiation of hematopoietic
stem cells
Goplen et al., 2012 E1 = E2 Yes Thymocytes Th2 differentiation, asthma
erk2 GENE DISRUPTION IN WHOLE MICE
Saba-El-Leil et al., 2003 Embryonic lethality, placenta development
Yao et al., 2003 Embryonic lethality, mesoderm differentiation
Hatano et al., 2003 Embryonic lethality, placenta development
Lips et al., 2004 Not done Yes (IP) (Loss of only one erk2 allele)
ischemia-reperfusion injury, infarction
Purcell et al., 2007 E2 > E1 Yes (Loss of only one erk2 allele) cardiac
hypertrophic growth response
erk1 AND erk2 DISRUPTION IN CELLS
Chen H. et al., 2015 E2 > E1 Not done Self-renewal, genome stability and pluripotency
of mouse ESCs
erk2 GENE DISRUPTION IN TISSUES
Satoh et al., 2007 Not done Not done EIIA–Cre + partial ERK2 Long term memory, fear conditioning
Newbern et al., 2008 Not done Not done Wnt1:Cre (neural crest) Developmental defects
Samuels et al., 2008 Not done Not done hGFAP–(neural progenitor) Proliferation, differentiation, cognition, memory
formation
Satoh et al., 2009 E2 = E1 Yes EIIA-Cre Re-epithelization, burn healing, keratinocytes
proliferation
Hamilton et al., 2013 E2 > E1 Yes Get embryonic stem cells Pluripotency-associated transcripts
Ulm et al., 2014 On 2 gels Not clear MLC2v-CRE (cardiomyocyte) Hypertrophic remodeling of cardiomyocytes,
apoptosis
Frémin et al., 2015 E2 > E1 Yes Sox2:Cre (whole embryo) Embryo development with normal placenta
erk2 GENE DISRUPTION IN TISSUES IN MICE LACKING erk1 GENE
Fischer et al., 2005 Not done Not done Cd4-Cre and Lck-Cre CD4 and CD8 T-cell lineage commitment
Ishii et al., 2012 Not done Not done CNP-Cre Myelin growth, oligodendrocyte differentiation
(Continued)
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TABLE 2 | Continued
Refernces ERK1/2 ratio Effect on
phospho-ERKs
Promoter of Cre recombinase Main phenotypes
Fan et al., 2009 E2 > E1 Yes Cyp19-Cre Oocyte activation, ovulation, luteinization
D’Souza et al., 2008 Not done Not done dLck-iCre CD8 T-cell activation, proliferation and survival
Matsushita et al., 2009 Not done Not done Col2a1-Cre and Prx1-Cre Lineage specification of
osteo-chondroprogenitor, osteoblast
Srinivasan et al., 2009 Not done Not done Tie2-Cre Endothelial cell proliferation, migration during
angiogenesis
Imamura et al., 2010 Not done Not done Nestin-Cre Cortical brain development
Blasco et al., 2011 E1 ≥ E2 Yes Cre-adenoV + inducible
Cre-ERT2
K-Ras induced tumors in lungs, mice death
upon KO in adulthood
Sebastian et al., 2011 Not done Not done Col2a1-Cre Growth of cartilaginous skeletal elements,
synchondrosis closure
Fyffe-Maricich et al.,
2011
Not done Not done hGFAP–Cre+ NG2–Cre
(=Cspg4Cre)
Differentiation/proliferation of oligodendrocytes,
myelination
He et al., 2011 E1 > E2 Yes Mx1-Cre Osteoclast differentiation, adhesion, migration,
bone resorption
Satoh et al., 2011b Not done Not done Nestin-Cre Brain development, behavior
Satoh et al., 2011a E2 > E1 Yes Nestin-Cre and EIIA-Cre Social behaviors and learning disabilities
Kehat et al., 2011 E1 ≥ E2 Yes Nkx2.5-Cre Cardiac hypertrophy, lengthening vs thickening
of myocytes
Otsubo et al., 2012 E2 > E1 Yes Nestin-Cre Responses to pain models
Chan et al., 2013 Not done Not done Mx1-Cre Hematopoietic stem cells proliferation,
differentiation, aplasia
Staser et al., 2013 Not done Not done Mx1-Cre Hematopoietic stem cells proliferation and
differentiation (HSPCs)
Richardson et al., 2015 E1 ≥ E2 Yes Lyz2-Cre Proliferation of bone marrow progenitors,
macrophages induction
O’Brien et al., 2015 Not in all Not in all Nav1.8-Cre Inflammatory pain, sensory neurons
proliferation-differentiation
Chen Z. et al., 2015 Not done Not done Osx-Cre Chondrocyte terminal differentiation,
enchondromas
“ERK1/2 ratio” and “Effect on phospho-ERKs” (2nd and 3rd column) are presented as in Table 1.The promoters driving Cre-recombinase in mice are presented in 4th column. Upon
crossing these mice with erk2floxed/floxed mice, erk2 gene will be invalidated in the tissues expressing the recombinase. Only the main phenotypes studied are presented (last column).
of macrophages, however in mice lacking ERK1, the only
macrophages that were encountered were those that did not
lose ERK2 (failure of Cre-recombinase to invalidate erk2 gene;
Richardson et al., 2015). In osteoclasts, He et al. (2011) have
demonstrated that ERK1 is markedly more expressed than ERK2
and only erk1−/− osteoblast display a clear reduction of the global
ERK activity. Indeed only in erk1−/− cells they observed that
the ERK substrate p90RSK is less phosphorylated and osteoclast
differentiation and bone resorptive activity is reduced. Kehat
et al. (2011) have shown that global invalidation of ERK1 and
ERK2 was necessary to regulate the balance between eccentric
and concentric growth of the heart. They did not assess the
contribution isoforms to regulate this balance.
Focusing on ERK2-targeted cells/tissues that express more
ERK2, for example, in granulosa cells of mouse ovaries, Fan et al.
showed that invalidation of ERK2 or ERK1 partially reduced
global ERK activation whereas invalidation of both isoforms
abrogated ERK activity (Figure S1A of Fan et al., 2009). Then
they demonstrated that maturation of ovocytes and birth of mice
pups was abrogated only when both isoforms were invalidated.
Interestingly, oocyte maturation occurred nearly normally when
global ERK signaling in granulosa cells was provided either by a
single ERK1 allele or two alleles of erk2 (no experiment with only
one allele of erk2 was presented). Considering the care of these
authors to show global activation levels in different mice lines,
these results clearly argue for a redundant role of ERK isoforms
in mouse granulosa cells (Fan et al., 2009).
Satoh et al. invalidated erk2 in mice brain and observed
abnormal social behavior of these mice and impairment of
long-term memory (Satoh et al., 2011a). erk2 disruption led
to increased ERK1 activation measured by anti phospho-
ERK antibody. To study ERK1 contribution, these authors
injected a MEK inhibitor intraperitoneally and observed that 1 h
later the levels of phospho-ERKs in the hippocampus, cortex
and cerebellum were reduced. In animals lacking ERK2, the
inhibitor did not modify the phenotype observed, this result
was interpreted by the authors as a failure of ERK1 to drive
these behavioral and memory features (especially because ERK1
was over-activated in these brain regions of erk2−/−(brain) mice;
Satoh et al., 2011a). An alternative explanation could be that
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a minimal threshold of global ERK activity for phenotype was
already reached in animals lacking ERK2, impeding further
behavioral damage. Indeed these authors did not show that
the limit of behavioral damage could be increased further than
what was observed after erk2 disruption. With the same model,
Ostubo et al. studied the nociceptive response in mice and also
implicated ERK2 but not ERK1, again because pharmacological
inhibition did not increase the erk2−/−(brain) phenotype (Otsubo
et al., 2012). However, in the same laboratory, Satoh et al.
showed that the sole deficiency of ERK2 in mice disrupted
mildly brain development, however further invalidation of ERK1
aggravated the phenotype leading to death within 1 day after
birth (the pups failed to breast-feed in double knock-outmice). In
these brain areas, ERK2 was more expressed than ERK1. Hence
with this model of single vs. dual invalidation, these authors
conclude that total ERK activity, and not a specific ERK isoform,
governs cellular behaviors to ensure proper brain development
(Satoh et al., 2011b). Hamilton and co-workers invalidated ERK2
expression in mouse embryonic stem cells that express more
ERK2 and showed that cells lacking ERK2 displayed enhanced
self-renewal capacity and remained even more undifferentiated
(Hamilton et al., 2013). Interestingly, these phenotypes were
reversed by re-expression of either ERK1 or ERK2 arguing again
in favor of isoform redundancy.
In the remaining 13 publications that study consequences of
erk2 gene disruption by recombinase in a specific tissue, the
ratio between isoforms was not presented. However, 6 of these
studies aimed at determining the role of global ERK activity,
not isoform contributions in biological processes (Fischer et al.,
2005; Matsushita et al., 2009; Srinivasan et al., 2009; Sebastian
et al., 2011; Chan et al., 2013; Chen Z. et al., 2015), and 4 studies
demonstrated that there is virtually no phenotype in single
mutants whereas in the double erk1+erk2 knockout phenotypes
are exacerbated, re-enforcing the notion of isoform functional
redundancy (Imamura et al., 2010; Satoh et al., 2011b; Ishii
et al., 2012; Staser et al., 2013). Three remaining publications
conclude for a specific role of ERK2 (out of 13 that did not
quantify isoform ratios), however from our point of view, the
lack of measurement of ERK1/ERK2 ratio does not allow to draw
clear cut conclusions (D’Souza et al., 2008; Fyffe-Maricich et al.,
2011; O’Brien et al., 2015). Furthermore, in a given tissue Cre
recombinase expression may not invalidate alleles in all cells.
Therefore, it is mandatory to measure to which extent global
ERK activity is effectively decreased following mice crossings.
This is particularly obvious in light of the minimal decrease of
ERK activity observed by O’Brien et al. in dorsal root ganglia of
mouse invalidated for ERK2 (Figure 5A of O’Brien et al., 2015).
In that study, only phenotypes of animals lacking both isoforms
allow to conclude that ERK is essential for sensory neuron
biology.
Conclusions from erk1, erk2 Gene Disruptions in Mice
When taking into account the isoform ratio and effectiveness
to reduce global ERK activity, the studies presenting disruption
of erk1/2 alleles in mice, give overwhelmingly credit toward
functional redundancy between ERK1 and ERK2.
Isoform Loss in Vertebrates
As described above, silencing experiments in cells and gene
disruption in mice provide strong arguments for a functionally
redundant role of ERK isoforms, furthermore, deletion of
erk1 gene in laboratory mice is compensated by increase of
endogenous ERK2 activity to allow normal development and
reproduction. Therefore, one can wonder why all mammals
analyzed so far have kept expression of both ERK1 and
ERK2? We have used another approach to investigate this
question by obtaining insights from vertebrate evolution
(Busca et al., 2015).
First it is striking that cartilaginous fishes, birds and frogs
do not possess erk1 genes, confirming that vertebrate life is
compatible with total loss of one isoform. All other vertebrates
analyzed so far possess erk1 and erk2 genes. The high expression
level of ERK proteins, and the availability of anti-phospho ERK
antibodies allowed to determine expression of isoforms in all
vertebrates (the phospho ERK epitope is 100% conserved in
vertebrates; Busca et al., 2015). In reptiles, two species of turtles
express both ERK1 and ERK2, but crocodiles do not express
ERK1 at detectable levels, and more surprisingly no ERK2
protein was detected in squamates (snakes lizards and geckos).
In lizards, ERK2 was not present in all brain areas studied and
all adult tissues tested (it is important to note that ERK is
highly expressed in the brain). To confirm unambiguously this
observation, only siRNA targeting ERK1 reduced ERK protein
expression in lizard embryo fibroblasts. As controls, the pools of
siRNA targeting ERK1 or ERK2 were able to reduce the level of
their respective RNAs. The strength of erk proximal promoters
were compared (about 1 kb upstream initiating ATG). In lizards,
erk2 promoter is markedly weaker than erk1 promoter, whereas
it is the opposite for mouse promoters (Busca et al., 2015).
Therefore, in vertebrates, ERK signal can be provided either by
both isoforms or only by ERK1 or ERK2. One reason explaining
the predominance of isoforms lies at least on the strength of their
respective promoters.
The question can be turned up-side down: why most
vertebrates express functionally redundant ERK isoforms? As
presented above, ERK1 and ERK2 isoforms appeared about 400
million years ago in the course of whole genome duplication
(WGD) in early vertebrates. Most duplicate genes are lost
progressively during evolution of species; however after a WGD
the loss of duplicated genes is slower than gene loss after local
duplication (Blomme et al., 2006). Indeed, from studying WGD
in paramecium, it was shown that duplicates with no divergent
functions can be kept for of millions of years; interestingly
genes were shown to be kept longer as duplicates if they are
highly expressed and/or if they belong to signaling cascades
(Aury et al., 2006; Brunet et al., 2006). Therefore, considering
that ERK1 and ERK2 are both highly expressed and signaling
molecules, they are good candidates to be kept as duplicates for
many millions of years, even without being endowed with novel
functions nor sub-functionalization. Nonetheless, duplicates can
still be lost when dosage is provided by one isoform, already
cartilaginous fishes, birds and frogs have lost the gene one erk
isoform. Will a wild mammal lacking one erk gene ever be
found?
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Phylogenic studies revealed that ERK1 and ERK2 nucleotide
sequences evolved at similar rates, but the sequences of ERK1
proteins evolved faster than those of ERK2 proteins. This could
indicate a less important/dispensable role of ERK1. However,
it should be noted that among all vertebrate MAP kinases,
ERK2 sequences are the most stable ones, and the rate of ERK1
sequences evolution is still very low, in the range measured for
all p38-MAP kinases (Li et al., 2011). By aligning sequences
on ERK1’s 3D structure, it was shown that the few positions
displaying variable amino-acids among mammalian ERK1s are
all located on the back of the kinase, away from domains
that bind to activators and substrates and away from kinase
effector domains. Therefore, positions essential for all known
functions are invariant in vertebrate ERK1 and ERK2 sequences,
arguing against isoform-specific functional differences. In most
vertebrates, and especially in mammals, erk2 genes are much
larger than erk1 (15 fold) providing a structural explanation (and
not a functional one), for the slower evolution rate of ERK2
protein sequences, since larger genes can recombine more easily
to purify mutations during evolution (Marais et al., 2005; Liao
et al., 2006).
Overall these phylogenic studies accredit the hypothesis
that ERK1 and ERK2 are functionally redundant kinases,
whose protein domains essential for function remain extremely
conserved across evolution.
Replacement of erk2 in Mice
In the three studies that have described the lethality of
erk2 gene disruption in mice (Hatano et al., 2003; Saba-El-
Leil et al., 2003; Yao et al., 2003), it was suggested that
ERK1 is insufficiently expressed at some developmental stages
to complement ERK2 loss to convey properly ERK signaling.
To validate this hypothesis, Frémin and co-workers intended
to express erk1 cDNA in the first exon of endogenous mouse
erk2 gene, which should have allowed expression of ERK1 at
the levels of endogenous ERK2 since the half-life of mouse ERK
mRNAs and mouse ERK proteins were shown to be very similar
(Schwanhausser et al., 2011). Unfortunately, neither erk1 cDNA,
nor a control erk2 cDNA, drove expression to levels near those
of endogenous erk2, precluding the use of these constructs to
generate mice.
However, these authors generated transgenic mice expressing
ERK1 under the control of the ubiquitously expressed chicken
beta-actin promoter (Frémin et al., 2015). In these mice,
transgenic-ERK1 was expressed in all early embryonic stages
to all adult tissues at elevated levels. Upon crossing these mice
with erk2+/− mice, it was possible to obtain mice lacking both
alleles of erk2 at Mendelian rates. They found that mice lacking
ERK2 lived and reproduced normally, establishing that ERK1
protein can replace ERK2 throughout all mammalian life. It is
very interesting to note that ERK1 seemed to be more expressed
in transgenic-ERK1 animals than ERK2 in wild-type animals,
however the global level of ERK activity was very similar in
both animal lines (Frémin et al., 2015). In few tissues such as
the heart, transgenic-ERK1 expression was much higher than
ERK2 expression in WT-animals, but global active ERK seemed
nearly identical in transgenic-ERK1 animals and WT ones
(Figure S3H in Frémin et al., 2015). This observation confirms
the high resiliency of ERK signaling to perturbations such as
over-expression of one component, at least in the absence of
challenging stimuli. In mouse embryo expressing transgenic-erk1
in erk2f/f background, the highly expressed ERK1 protein did
not change the expression of endogenous ERK2 but it captured
most of the activation from upstream MEK, illustrating clearly
again the resiliency of the pathway (ERK2 activation is markedly
diminished, Figure S3C in Frémin et al., 2015). This observation
demonstrates once more the equivalence of ERK1 and ERK2
isoforms to receive MEK activation. Furthermore, upon crossing
animals missing different alleles of ERK isoforms, these authors
have demonstrated that the extent of placental and embryonic
development is strictly correlated to global ERK activity (Frémin
et al., 2015).
The lethality of erk2 loss in mice can be compensated when
ERK1 expression is increased in all tissues. Then, there is a
tight correlation between global ERK activity and the phenotypes
observed, irrespectively of the isoform expressed. Taken together
these observations demonstrate functionally redundant roles for
ERK1 and ERK2 by this gene-replacement strategy.
CONCLUSIONS/PERSPECTIVES
Deregulation of the ERK signaling cascade is devastating for
many patients. Many clinical trials with inhibitors of Raf,
MEK and ERK are ongoing to overcome cancer, stressing the
importance in understanding all aspects of this signaling cascade.
At the level of Ras, several cancers are triggered almost
exclusively via mutation of a single isoform such as only K-
Ras mutations found in pancreatic cancers for example (Bryant
et al., 2014). At the level of Raf, pharmacological inhibitors
targeting a single isoform have been approved to treat patients.
At the level of MEK, distinct retro-phosphorylations provide a
rationale for having two isoforms. Overall, isoform specificities
play a significant role in this pathway, therefore the quest in
understanding why two isoforms convey ERK signaling appears
of great importance.
With regards to protein sequences, ERK1 and ERK2 are very
stable across evolution, with variations in amino-acids only at
positions that are neutral for function. Presently, neither ERK
isoform-specific agonists, nor isoform-specific substrates have
been found. These observations point again toward functional
redundancy of ERK1 and ERK2. However, these kinases are not
redundant per se since disruption of erk2 without compensation
by ERK1transgenic is lethal in mice. Indeed, ERK1 and ERK2 are
expressed ubiquitously but not at the same level in most tissues.
Clear differences between ERK1 and ERK2 are obvious at the
gene level. For example, in mammals erk2 genes are on average
15 times larger than erk1 genes, and in mice the 3-prime UTR of
erk2 is both 6 times larger than erk1 and possess an alternative
poly-adenylation site. These differences indicate that ERK2 has
the capacity to be more exquisitely regulated than ERK1. Apart
from these differences in expression levels, we cannot exclude
that very fine specializations exist between ERK1 and ERK2, such
as a slightly stronger affinity for a substrate or an interactor
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protein. Only replacement of all exons of one isoform with those
of the other isoform may uncover these fine differences; however
it might be very complicated to draw conclusions if the replaced
exons modify protein stability and change even slightly the global
ERK quantity/activity ratio!
The studies presented here using knock-down approaches
or gene disruptions overwhelmingly demonstrate a direct
correlation between a biological consequence and the global
level of ERK activation, irrespectively of the isoform. In cells
with complex fate such as a balance between proliferation and
differentiation, not all combinations have been studied so far.
For example one would have liked to compare knock-out of a
single erk2 allele with knock-out of both erk1 alleles; pending
these two conditions would decrease global ERK activation to
the same extent. Among three add-back studies presented here,
one concluded that transfection of either ERK1 or ERK2 could
reverse the phenotype of ERK2 loss, whereas the two other
studies were inconclusive since it was not demonstrated that
individual ERK transfections re-established the active ERK levels.
In our hands it has proven difficult to re-express ERK that can be
activated as efficiently as endogenous ERK (efficiency measured
as the percentage of the transfected kinase that is effectively
activated). Similarly, Meloche and co-workers did not succeed to
express ERK1 or ERK2 at normal levels from cDNA inserted in
mouse erk2 locus (Frémin et al., 2015). Further work is needed
to understand the means by which ERK proteins are highly
expressed and regulated.
In more than 75 studies, the decrease of ERK expression was
shown to trigger biological phenotypes, therefore it is surprising
that over-expression of ERK1 in mice does not cause apparent
phenotypical changes (Frémin et al., 2015)! We predict that
under challenging conditions, phenotypes will be discovered
in this ERK1-transgenic model. In fact, despite the elevated
quantity of ERK1 in these mice, global ERK activation level
seemed normal due to the robustness of the pathway via multiple
retro-inhibitions. However, ERK quantity needs to be regulated,
at least under challenging conditions. For example erk2 gene
amplification in humans was demonstrated to be the cause
of tumor resistance to cancer treatment (Ercan et al., 2012).
Therefore, more research is needed to understand the relevance
of global ERK quantity for proper signaling under challenging
conditions.
Lack of ERK is lethal in vertebrates but mice have been
generated without ERK1 protein or without ERK2 protein,
and tetrapods (vertebrates with four limbs) express either both
ERKs or only ERK1 or only ERK2. In many studies, a direct
correlation between the global quantity of ERK activation and
phenotypical consequences has been established. Taken together,
these data strongly suggest that ERK1 and ERK2 are functionally
redundant.
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